HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial

From: 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA 26-27 April, 2010 Author details1-University of KwaZulu Natal, Durban, South AfricaEMPTY2-CAPRISA and SA-Columbia Fogarty AITRPEMPTY3-Columbia University, New York, NY, USAEMPTY4-Yale University School of Medicine, New Haven, CT, USAEMPTY5-Harvard Medical School, Boston, MA, USAEMPTY6-Reproductive Health and HIV Research Unit, University of the Witwatersrand, Johannesburg, South AfricaEMPTY Supplemental Information: Complete or partial response was associated with increased global health scores (p